INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
This clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2015-01-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/768 |
| _version_ | 1797198000139796480 |
|---|---|
| author | S. P. Pyltsin E. Yu. Zlatnik Yu. N. Lazutin G. Z. Sergostyants G. I. Zakora I. A. Leyman P. A. Anistratov |
| author_facet | S. P. Pyltsin E. Yu. Zlatnik Yu. N. Lazutin G. Z. Sergostyants G. I. Zakora I. A. Leyman P. A. Anistratov |
| author_sort | S. P. Pyltsin |
| collection | DOAJ |
| description | This clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group received adjuvant chemoimmunotherapy accomplished with Ingaron, whereas 30 cases (48%) in control group were assigned to receive conventional adjuvant chemotherapy. Adjuvant chemoimmunotherapy was administered according to the following schedule: carboplatinum, AUC = 5 i.v. on day 1; etoposide, 100 mg/m2 i.v. on days 1,3,5; interferon-gamma, 500.000 I.E./m2 i.v. on days 2,4,6. In the patiens undergoing lobectomy, carboplatinum was replaced for cisplatinum 100 mg/m2 i.v. on day 1. Comparative evaluation of the both treatment regimens has shown a correcting effect of Ingaron upon cellular immunity links. The Ingaroncontaining chemoimmunotherapy may contribute to improvement of 3-year event-free survival among lung adenocarcinoma patients by 19 percent (p = 0.06607). |
| first_indexed | 2024-03-08T05:49:24Z |
| format | Article |
| id | doaj.art-1ff2316bfccd431f94678092ea31bdf8 |
| institution | Directory Open Access Journal |
| issn | 1563-0625 2313-741X |
| language | Russian |
| last_indexed | 2024-04-24T06:52:54Z |
| publishDate | 2015-01-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj.art-1ff2316bfccd431f94678092ea31bdf82024-04-22T13:07:39ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2015-01-0116655956610.15789/1563-0625-2014-6-559-566722INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPYS. P. Pyltsin0E. Yu. Zlatnik1Yu. N. Lazutin2G. Z. Sergostyants3G. I. Zakora4I. A. Leyman5P. A. Anistratov6Rostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationRostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationRostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationRostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationRostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationRostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationRostov/Don Research Institute of Oncology, Russian Ministry of Health Care, Rostov-on-Don, Russian FederationThis clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group received adjuvant chemoimmunotherapy accomplished with Ingaron, whereas 30 cases (48%) in control group were assigned to receive conventional adjuvant chemotherapy. Adjuvant chemoimmunotherapy was administered according to the following schedule: carboplatinum, AUC = 5 i.v. on day 1; etoposide, 100 mg/m2 i.v. on days 1,3,5; interferon-gamma, 500.000 I.E./m2 i.v. on days 2,4,6. In the patiens undergoing lobectomy, carboplatinum was replaced for cisplatinum 100 mg/m2 i.v. on day 1. Comparative evaluation of the both treatment regimens has shown a correcting effect of Ingaron upon cellular immunity links. The Ingaroncontaining chemoimmunotherapy may contribute to improvement of 3-year event-free survival among lung adenocarcinoma patients by 19 percent (p = 0.06607).https://www.mimmun.ru/mimmun/article/view/768lung adenocarcinomaadjuvant chemotherapychemoimmunotherapyinterferon-gamma |
| spellingShingle | S. P. Pyltsin E. Yu. Zlatnik Yu. N. Lazutin G. Z. Sergostyants G. I. Zakora I. A. Leyman P. A. Anistratov INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY Медицинская иммунология lung adenocarcinoma adjuvant chemotherapy chemoimmunotherapy interferon-gamma |
| title | INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY |
| title_full | INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY |
| title_fullStr | INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY |
| title_full_unstemmed | INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY |
| title_short | INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY |
| title_sort | influence of ingaron upon immune state of the patients with adenocarcinoma of lung in the course of adjuvant therapy |
| topic | lung adenocarcinoma adjuvant chemotherapy chemoimmunotherapy interferon-gamma |
| url | https://www.mimmun.ru/mimmun/article/view/768 |
| work_keys_str_mv | AT sppyltsin influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT eyuzlatnik influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT yunlazutin influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT gzsergostyants influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT gizakora influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT ialeyman influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy AT paanistratov influenceofingaronuponimmunestateofthepatientswithadenocarcinomaoflunginthecourseofadjuvanttherapy |